Buy & Sell Western Alliance Bancorporation (WAL) – Western Alliance Bancorporation Price Today
Aura AI Summary
Key Stats
- $8.59BMarket Cap
- FinancialsSector
- -18.22%3M Drawdown
- -Enterprise Value
- 2.14%Dividend Yield
- 3 daysTypical Hold Time
Western Alliance Bancorporation (WAL) is currently valued at a market capitalization of $8.59B. Over the past 52 weeks, Western Alliance Bancorporation has traded between a low of $66.7 and a high of $96.08, highlighting its annual price range. Over the past three months, Western Alliance Bancorporation has recorded a drawdown of -18.22%, reflecting recent price volatility. Western Alliance Bancorporation offers a dividend yield of 2.14%, with the most recent dividend of $0.42 paid on 14 May 26. On average, investors hold Western Alliance Bancorporation for approximately 3 days, indicating typical investor behavior on the platform.
About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Most Recent News
Universal Music Group rejects Pershing Square's undervalued buyout proposal, confident in growth strategy.
Universal Music Group's Board of Directors unanimously rejected an unsolicited buyout proposal from Pershing Square Capital Management, stating it undervalues the company and won't create superior value. The Board, supported by shareholders, highligh...

4% withdrawal rule risks vary with market timing; early losses can halve retirement savings.
A retiree with a $2.4 million portfolio following the 4% withdrawal rule faces significant sequence-of-returns risk. Early market downturns, like the 2000-2002 dot-com crash, can drastically reduce portfolio value despite average returns of 7%. Strat...

Actinium Pharmaceuticals updates on ATNM-400 cancer therapy and faces NYSE listing compliance challenges.
Actinium Pharmaceuticals announced new data presentations for its ATNM-400 targeted radiotherapy at the SNMMI 2026 Annual Meeting, highlighting its potential in prostate and non-small cell lung cancers. The company also disclosed a notice from NYSE A...
